Literature DB >> 23998344

An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.

R Selb1, J Eckl-Dorna, S Vrtala, R Valenta, V Niederberger.   

Abstract

BACKGROUND: It has been shown that birch pollen immunotherapy can induce IgG antibodies which enhance IgE binding to Bet v 1. We aimed to develop a serological assay to predict the development of antibodies which enhance IgE binding to Bet v 1 during immunotherapy.
METHODS: In 18 patients treated by Bet v 1-fragment-specific immunotherapy, the effects of IgG antibodies specific for the fragments on the binding of IgE antibodies to Bet v 1 were measured by ELISA. Blocking and possible enhancing effects on IgE binding were compared with skin sensitivity to Bet v 1 after treatment.
RESULTS: We found that fragment-specific IgG enhanced IgE binding to Bet v 1 in two patients who also showed an increase of skin sensitivity to Bet v 1.
CONCLUSION: Our results indicate that it may be possible to develop serological tests which predict the induction of unfavourable IgG antibodies enhancing the binding of IgE to Bet v 1 during immunotherapy.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bet v 1; birch pollen allergy; enhancing IgG antibodies; immunotherapy; recombinant allergen

Mesh:

Substances:

Year:  2013        PMID: 23998344      PMCID: PMC5321514          DOI: 10.1111/all.12204

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  11 in total

1.  Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction.

Authors:  S Denépoux; P B Eibensteiner; P Steinberger; S Vrtala; V Visco; A Weyer; D Kraft; J Banchereau; R Valenta; S Lebecque
Journal:  FEBS Lett       Date:  2000-01-07       Impact factor: 4.124

2.  Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.

Authors:  Anna Gieras; Petra Cejka; Katharina Blatt; Margarete Focke-Tejkl; Birgit Linhart; Sabine Flicker; Angelika Stoecklinger; Katharina Marth; Anja Drescher; Josef Thalhamer; Peter Valent; Otto Majdic; Rudolf Valenta
Journal:  J Immunol       Date:  2011-03-30       Impact factor: 5.422

3.  Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1.

Authors:  V Visco; C Dolecek; S Denépoux; J Le Mao; C Guret; F Rousset; M T Guinnepain; D Kraft; R Valenta; A Weyer; J Banchereau; S Labecque
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

Review 4.  From allergen genes to allergy vaccines.

Authors:  Rudolf Valenta; Fatima Ferreira; Margarete Focke-Tejkl; Birgit Linhart; Verena Niederberger; Ines Swoboda; Susanne Vrtala
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.

Authors:  S Vrtala; C A Akdis; F Budak; M Akdis; K Blaser; D Kraft; R Valenta
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

7.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

Authors:  Gabrielle Pauli; Tina H Larsen; Sabina Rak; Friedrich Horak; Elide Pastorello; Rudolf Valenta; Rudolph Valenta; Ashok Purohit; Monica Arvidsson; Alexander Kavina; Jan W Schroeder; Nadine Mothes; Susanne Spitzauer; Armelle Montagut; Sylvie Galvain; Michel Melac; Claude André; Lars K Poulsen; Hans-Jorgen Malling
Journal:  J Allergy Clin Immunol       Date:  2008-11       Impact factor: 10.793

Review 8.  Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.

Authors:  Rudolf Valenta; B Linhart; I Swoboda; V Niederberger
Journal:  Allergy       Date:  2011-02-26       Impact factor: 13.146

9.  Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.

Authors:  M H Shamji; C Ljørring; J N Francis; M A Calderon; M Larché; I Kimber; A J Frew; H Ipsen; K Lund; P A Würtzen; S R Durham
Journal:  Allergy       Date:  2011-11-14       Impact factor: 13.146

Review 10.  Safety of engineered allergen-specific immunotherapy vaccines.

Authors:  Margarete Focke-Tejkl; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-10
View more
  4 in total

1.  Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects.

Authors:  Zsolt Szépfalusi; Christina Bannert; Leila Ronceray; Elisabeth Mayer; Michaela Hassler; Eva Wissmann; Eleonora Dehlink; Saskia Gruber; Alexandra Graf; Christian Lupinek; Rudolf Valenta; Thomas Eiwegger; Radvan Urbanek
Journal:  Pediatr Allergy Immunol       Date:  2014-12       Impact factor: 6.377

Review 2.  Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy.

Authors:  Katharina Marth; Margarete Focke-Tejkl; Christian Lupinek; Rudolf Valenta; Verena Niederberger
Journal:  Curr Treat Options Allergy       Date:  2014-02-26

3.  Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Jiun-Bo Chen; Louisa K James; Anna M Davies; Yu-Chang Bryan Wu; Joanne Rimmer; Valerie J Lund; Jou-Han Chen; James M McDonnell; Yih-Chih Chan; George H Hutchins; Tse Wen Chang; Brian J Sutton; Harsha H Kariyawasam; Hannah J Gould
Journal:  J Allergy Clin Immunol       Date:  2016-09-19       Impact factor: 10.793

Review 4.  Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses.

Authors:  Julia Eckl-Dorna; Sergio Villazala-Merino; Birgit Linhart; Alexander V Karaulov; Yury Zhernov; Musa Khaitov; Verena Niederberger-Leppin; Rudolf Valenta
Journal:  Front Immunol       Date:  2019-01-17       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.